Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning

Bone Marrow Transplantation

Volumn 36, Issue 3, 2005, Pages 215-225

  Steiner, M ^a   Matthes Martin, S ^a   Attarbaschi, A ^a   Minkov, M ^a   Grois, N ^a   Unger, E ^a   Holter, W ^b   Vormoor, J ^c   Wawer, A ^d   Ouachee, M ^e   Woessmann, W ^f   Gadner, Helmut ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Langerhans cell histiocytosis; Nonmyeloablative; Reduced intensity; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; ANTIHYPERTENSIVE AGENT; BUSULFAN; CYCLOSPORIN A; ETANERCEPT; FLUDARABINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REGIMEN; FATALITY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTIOCYTOSIS X; HUMAN; HYPERTENSION; INFANT; LYMPH NODE IRRADIATION; MALE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; SEPSIS; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS PNEUMONIA; WHOLE BODY RADIATION;

FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; LANGERHANS CELLS; MALE; MELPHALAN; PROGNOSIS; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 23744481272     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705015     Document Type: Article

References (38)

1. Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer 1999; 35: 747-767; discussion 767-769.
2. Egeler RM, Favara BE, van Meurs M et al. Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 1999; 94: 4195-4201.
3. Favara BE, Jaffe R, Egeler RM. Macrophage activation and hemophagocytic syndrome in langerhans cell histiocytosis: report of 30 cases. Pediatr Dev Pathol 2002; 5: 130-140.
4. Gadner H, Heitger A, Grois N et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994; 23: 72-80.
5. Gadner H, Grois N, Arico M et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001; 138: 728-734.
6. Minkov M, Grois N, Heitger A et al. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002; 39: 581-585.
7. Gadner H. Langerhans' cell histiocytosis - still an unsolved problem. Pediatr Hematol Oncol 1999; 16: 489-493.
8. Minkov M, Grois N, Broadbent V et al. Cyclosporine A therapy for multisystem langerhans cell histiocytosis. Med Pediatr Oncol 1999; 33: 482-485.
9. Ringden O, Ahstrom L, Lonnqvist B et al. Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X. N Engl J Med 1987; 316: 733-735.
10. Stoll M, Freund M, Schmid H et al. Allogeneic bone marrow transplantation for Langerhans'cell histiocytosis. Cancer 1990; 66: 284-288.
11. Greinix HT, Storb R, Sanders JE, Petersen FB. Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis. Bone Marrow Transplant 1992; 10: 39-44.
12. Frost JD, Wiersma SR. Progressive Langerhans cell histiocytosis in an infant with Klinefelter syndrome successfully treated with allogeneic bone marrow transplantation. J Pediatr Hematol Oncol 1996; 18: 396-400.
13. Conter V, Reciputo A, Arrigo C et al. Bone marrow transplantation for refractory Langerhans' cell histiocytosis. Haematologica 1996; 81: 46-71.
14. Broadbent V, Ladisch S. Results of the Histiocyte Society BMT salvage therapy questionnaire. Med Pediatr Oncol 1998; 31: 45 (abstr.).
15. Egeler RM, Anderson RA, Wolff JEA et al. Allogeneic peripheral blood stem cell transplantation in Langerhans cell histiocytosis. Med Pediatr Oncol 1999; 32: 238 (abstr.).
16. Ayas M, Mustafa M, Al-Mahr M, Solh H. Bone marrow transplantation as a salvage therapy for refractory disseminated Langerhans histiocytosis. Med Pediatr Oncol 1999; 32: 238 (abstr.).
17. Kinugawa N, Imashuku S, Hirota Y et al. Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan. Bone Marrow Transplant 1999; 24: 935-938.
18. Suminoe A, Matsuzaki A, Hattori H et al. Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2001; 23: 633-636.
19. Nagarajan R, Neglia J, Ramsay N, Baker KS. Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation. J Pediatr Hematol Oncol 2001; 23: 629-632.
20. Hale GA, Bowman LC, Woodard JP et al. Allogeneic bone marrow transplantation for children with histiocytic disorders: use of TBI and omission of etoposide in the conditioning regimen. Bone Marrow Transplant 2003; 31: 981-986.
21. Akkari V, Donadieu J, Piguet C et al. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant 2003; 31: 1097-1103.
22. Amrolia P, Gaspar HB, Hassan A et al. Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 2000; 96: 1239-1246.
23. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162.
24. Meyer-Wentrup F, Foell J, Wawer A, Burdach S. Unrelated cord blood transplantation in an infant with severe multi-system Langerhans cell histiocytosis: clinical outcome, engraftment and culture of monocyte-derived dendritic cells. Bone Marrow Transplant 2004; 33: 875-876.
25. Histiocytosis syndromes in children. Writing Group of the Histiocyte Society. Lancet 1987; 1: 208-209.
26. Broadbent V, Gadner H, Komp, DM, Ladisch S. Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol 1989; 17: 492-495.
27. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin N Am 1998; 12: 327-338.
28. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
29. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
30. Lansky SB, List MA, Lansky LL et al. The measurement of performance in childhood cancer patients. Cancer 1987; 60: 1651-1656.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
32. Egeler RM, Favara BE, Laman JD, Claassen E. Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. Eur J Cancer 2000; 36: 2105-2110.
33. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl 1994; 23: S37-40.
34. Nezelof C, Basset F. An hypothesis Langerhans cell histiocytosis: the failure of the immune system to switch from an innate to an adaptive mode. Pediatr Blood Cancer 2004; 42: 398-400.
35. Rao K, Nanduri V, Brock P et al. Bone marrow transplant as salvage for multisystem Langerhans cell histiocytosis. Pediatr Blood Cancer 2004; 43: 196 (abstr.).
36. Matthes-Martin S, Lion T, Haas OA et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003; 17: 1934-1942.
37. Jordan MB, McClain KL, Xiaotian Y et al. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer 2005; 44: 251-254.
38. Henter JI, Karlen J, Calming U et al. Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med 2001; 345: 1577-1578.